A recent Federal Court decision has struck down a patent term extension granted to Novartis for its blockbuster heart failure drug Entresto. The decision in Novartis AG v Pharmacor Pty Limited follows a recent trend of successful challenges by generic pharmaceutical companies. ...

HMC has agreed to acquire 100% of Global Switch Australia Holdings (GSA) as part of its broader strategy to establish a global digital infrastructure platform. GSA's two adjoining data centres in ...

IP Australia has published the outcomes of its 2023 consultation, which sought stakeholder feedback on a series of significant proposed changes to the Designs Act 2003 (Cth). These included provisions for virtual, partial and incremental designs, which it plans to pursue. ...

The firm acted as consortium counsel for Macquarie Asset Management-managed The Infrastructure Fund, State Super and Australian Retirement Trust on the sale of their combined interest to a consorti ...

In this Insight, we summarise the Report findings and highlight key factors for businesses to consider in managing their IP risks and IP opportunities. ...

IP Australia has announced sweeping changes to the amount and timing of official fees for patents, trade marks, designs and plant breeders' rights, as well as changes to fees and recoverable costs for oppositions. The changes will come into effect 1 October 2024. ...

Webinar: The IP landscape: Key trends and cases (part 2) ...

Webinar: Unpacking the world first decision: Australia says ‘yes’ to AI inventors ...

Webinar: 2024 retail webinar: unfair dealings, data compliance and IP challenges ...

Webinar: Mastering IP opportunities and risks in the age of AI ...